<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958812</url>
  </required_header>
  <id_info>
    <org_study_id>DPCVC</org_study_id>
    <nct_id>NCT03958812</nct_id>
  </id_info>
  <brief_title>Diagnostic Power Comparison Between VOCs and CTCs</brief_title>
  <official_title>The Diagnostic Power of VOCs Compared With CTCs for Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technion, Israel Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anhui Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early diagnosis of malignant tumors is pivotal for improving their prognoses. Circulating
      tumor cells (CTC) in peripheral blood and Volatile organic compounds (VOCs) in exhaled breath
      are newly developed diagnosis method. Due to the low percentage of CTCs in peripheral blood
      of cancer patients and the surface structure of lymphocytes (especially megakaryocytes) is
      often confused with tumor cells, CTC has a high false positive and negative rate. In recent
      years, the detection of volatile organic compounds (VOCs) in exhaled breath as a simple and
      noninvasive method has shown broad application prospects in the diagnosis of various
      diseases. A series of studies of VOCs diagnosing solid tumors the investigators had conducted
      in the past decade show that VOCs can not only distinguish different types of tumors, but
      also can make a distinction between different stages. This study was to compare CTC and VOCs
      with clinical samples. Predictive models will be built employing discriminant factor analysis
      (DFA) pattern recognition method. Sensitivity and specificity will be determined using
      leave-one-out cross-validation or an independent blind test set.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      200 patients with definitive diagnoses will be enrolled and the alveolar exhaled breath
      samples and peripheral venous blood will be collected. Two blood samples and two breath
      samples will be collected from each patient. One blood sample will be send to CTC tests for a
      blind test and the other will be used for headspace VOCs analyses. One breath sample was used
      for analysis with the Nano-sensors array, and the other was used for gas chromatography
      coupled with mass spectrometry (GC-MS) analysis. The VOCs samples were collected using
      sorbent tubes at a total flow through sorption trap of 200ml/min, then will be send to Israel
      Institute of Technology for further test.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Discrimination between Malignant and Benign Gastric/Breast Lesions and normal group with each diagnostic method (Na-nose/GC-MS/CTC)</measure>
    <time_frame>From June 15,2019 to June 1,2020</time_frame>
    <description>Exhaled breath samples and peripheral venous blood collected will be used to build predictive models employing discriminant factor analysis (DFA) and thereafter examine the sensitivity and specificity of model identification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comprehensive diagnostic model of VOCs and CTCs</measure>
    <time_frame>From June 1,2020 to Dec 31,2020</time_frame>
    <description>Organize predictive models of VOCs/CTCs and establish Comprehensive Diagnostic Model.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Circulating Tumor Cell</condition>
  <condition>Volatile Organic Chemicals</condition>
  <condition>Breast Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>Gastric cancer</arm_group_label>
    <description>patients with definitive diagnosis of gastric cancer by pathology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <description>patients with definitive diagnosis of breast cancer by pathology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign gastric diseases</arm_group_label>
    <description>Gastritis or gastric ulcer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign breast diseases</arm_group_label>
    <description>Hyperplasia of mammary glands or mastitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Circulating tumor cells, Volatile organic compounds</intervention_name>
    <description>Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients</description>
    <arm_group_label>Benign breast diseases</arm_group_label>
    <arm_group_label>Benign gastric diseases</arm_group_label>
    <arm_group_label>Breast cancer</arm_group_label>
    <arm_group_label>Gastric cancer</arm_group_label>
    <arm_group_label>Normal</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        200 patients or volunteers who undergo Gastroscopy or breast surgery in Anhui Provincial
        cancer hospital, Hefei, China
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years

          -  Definitive diagnosis of gastric cancer, breast cancer,benign breast disease and
             gastric lesions

          -  ECOG(Eastern Cooperative Oncology Group) scores â‰¤ 2

        Exclusion Criteria:

          -  Other palliative chemotherapy and radiotherapy for this cancer

          -  Other cancer

          -  Diabetes, Fatty liver

          -  Autoimmune disease

          -  Pulmonary ventilation dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hu Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anhui Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chuyang Bao, MD</last_name>
    <phone>+86 18555039598</phone>
    <email>des_mond@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hu Liu, MD</last_name>
    <phone>+86 13866175691</phone>
    <email>drliuhu@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Barash O, Zhang W, Halpern JM, Hua QL, Pan YY, Kayal H, Khoury K, Liu H, Davies MP, Haick H. Differentiation between genetic mutations of breast cancer by breath volatolomics. Oncotarget. 2015 Dec 29;6(42):44864-76. doi: 10.18632/oncotarget.6269.</citation>
    <PMID>26540569</PMID>
  </reference>
  <reference>
    <citation>Amal H, Shi DY, Ionescu R, Zhang W, Hua QL, Pan YY, Tao L, Liu H, Haick H. Assessment of ovarian cancer conditions from exhaled breath. Int J Cancer. 2015 Mar 15;136(6):E614-22. doi: 10.1002/ijc.29166. Epub 2014 Sep 5.</citation>
    <PMID>25159530</PMID>
  </reference>
  <reference>
    <citation>Nakhleh MK, Amal H, Jeries R, Broza YY, Aboud M, Gharra A, Ivgi H, Khatib S, Badarneh S, Har-Shai L, Glass-Marmor L, Lejbkowicz I, Miller A, Badarny S, Winer R, Finberg J, Cohen-Kaminsky S, Perros F, Montani D, Girerd B, Garcia G, Simonneau G, Nakhoul F, Baram S, Salim R, Hakim M, Gruber M, Ronen O, Marshak T, Doweck I, Nativ O, Bahouth Z, Shi DY, Zhang W, Hua QL, Pan YY, Tao L, Liu H, Karban A, Koifman E, Rainis T, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Tolmanis I, Johnson D, Millstone SZ, Fulton J, Wells JW, Wilf LH, Humbert M, Leja M, Peled N, Haick H. Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. ACS Nano. 2017 Jan 24;11(1):112-125. doi: 10.1021/acsnano.6b04930. Epub 2016 Dec 21.</citation>
    <PMID>28000444</PMID>
  </reference>
  <reference>
    <citation>Leja MA, Liu H, Haick H. Breath testing: the future for digestive cancer detection. Expert Rev Gastroenterol Hepatol. 2013 Jul;7(5):389-91. doi: 10.1586/17474124.2013.811033.</citation>
    <PMID>23899275</PMID>
  </reference>
  <reference>
    <citation>Amal H, Leja M, Broza YY, Tisch U, Funka K, Liepniece-Karele I, Skapars R, Xu ZQ, Liu H, Haick H. Geographical variation in the exhaled volatile organic compounds. J Breath Res. 2013 Dec;7(4):047102. doi: 10.1088/1752-7155/7/4/047102. Epub 2013 Nov 1.</citation>
    <PMID>24184568</PMID>
  </reference>
  <reference>
    <citation>Amal H, Ding L, Liu BB, Tisch U, Xu ZQ, Shi DY, Zhao Y, Chen J, Sun RX, Liu H, Ye SL, Tang ZY, Haick H. The scent fingerprint of hepatocarcinoma: in-vitro metastasis prediction with volatile organic compounds (VOCs). Int J Nanomedicine. 2012;7:4135-46. doi: 10.2147/IJN.S32680. Epub 2012 Jul 30.</citation>
    <PMID>22888249</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Anhui Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Hu Liu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>CTCs</keyword>
  <keyword>VOCs</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>diagnoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

